was added nearly saturating the human IL-17A on the surface. To determine whether ixekizumab blocks human IL-17A binding to human IL-17RA, ixekizumab at 500 nM was first injected to nearly saturate the human IL-17A surface followed by an injection of human IL-17RA/Fc at 1 µM.